C 53 H 50 F 2 N 6 O 10 S 2 , monoclinic, P21/n (no. 14), a = 15.088 (5) Å, b = 23.560(9) Å, c = 15.401(6) Å, β = 112.254(5)°, V = 5067(3) Å 3 , Z = 4, Rgt(F) = 0.0509, wR ref (F 2 ) = 0.1336, T = 298(2) K.
CrysAlis PRO [1] , SHELX [2, 3] (14) 0.20896(9) 0.44160 (15) 0.0429(5) C3 0.89913 (14) 0.21956(9) 0.47478 (17) 0.0464(5) C4 0.81519 (14) 0.18021(9) 0.44418 (15) 0.0428(5) C5 0.83011 (15) 0.12332 (9) The anti-inflammatory activities of title compound were evaluated by inhibition of LPS-induced NO secretion on mouse RAW264.7 macrophages. Pyrrolidine dithiocarbamate (PDTC) was used as a reference standard. In preliminary experiments, the title compound had no significant toxicity at 6.0 M on RAW264.7 cells. RAW264.7 cells were pretreated with 30 M of PDTC or with 6.0 M of title compound for 2.0 h. After treatment with LPS (1.0 g/mL) for 22 h, the collected culture media were centrifuged at 1000 rpm for 10 min. The expression levels of NO secretion in the media were determined by ELISA with an ELISA kit (eBioScience, San Diego, CA). The experiment was carried out in triplicate.
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In order to overcome low bioactivities, poor aqueous solubility and false positive problem of curcumin [4] , a series of novel curcumin analogues have been reported, such as 3E, 5E)-3,5-bis(arylidene)-4-piperidone derivatives (BAPs). BAPs contain two α,β-unsaturated keto groups, and show greater predilection or sequential interaction for bio-thiols in tumors rather than normal cell [5, 6] . In previous study, some BAPs were reported as better antitumor and anti-inflammatory agents [7] [8] [9] . Some strong electron-withdrawing substituent groups (Such as -NO 2 , -CN, -CF 3 ) were assigned to both sides of BAPs. Their antitumor and anti-inflammatory activity were improved to different extent. Some crystal structure and bioactivity of 4-((E)-((E)-5-(2-fluorobenzylidene)-1-((4-fluorophenyl)sulfonyl)-4-oxopiperidin-3-ylidene)methyl) benzonitrile (BAP-1), (3E,5E)-3,5-bis(4-cyanobenzylidene)-1-((4-fluorophenyl)sulfonyl)piperidin-4-one (BAP-2), (3E,5E)-3,5-bis(3-nitrobenzylidene)-1-((4-(trifluoromethyl) phenyl) sulfonyl)piperidin-4-one (BAP-3) were reported [10] [11] [12] .
When changing one side of BAPs to 3-pyridine substituents, while another side of BAPs is 2-F group, dissymmetric BAPs could be generated [8] . By adding the N-phenylsulfonyl moiety [13] , the desired and improved antitumor activities and anti-inflammatory activity of BAPs could be found. In this study, we report the crystal structure and anti-inflammatory activity of (3E,5E)-3-(2-fluorobenzylidene)-1-((4-acetamidophenyl)sulfonyl)-5-(pyridin-3-ylmethylene) piperidin-4-one.
Single-crystal structure analysis reveals that there are two BAP molecules, a methanol and a water molecule in the asymmetric unit of the title crystal structure (cf. the figure). Bond lengths and angles are all in the expected ranges. The central 3,5-bis(arylidene)-4-piperidone scaffold is lengthened on both sides in a linear fashion, with the pyridyl and arylidene substituents adopting the E stereochemistry of the olefinic double bonds [14, 15] . The dihedral angles between the pyridyl and central piperidone rings of the symmetry independent molecules are 57.5(3)°and 50.1(4)°, while the dihedral angles between arylidene and central piperidone are 24.1(3)°and 22.5(2)°, respectively. In addition, the N-phenylsulfonyl substituents stretch in the direction of the carbonyl group of central piperidone, giving an overall shape of an "organic clip" [16] . The dihedral angles between Nphenylsulfonyl group and piperidone ring are 38.7(3)°and 27.6(4)°, respectively.
According to the literature, the production of proinflammatory cytokines, such as express rate of NO production, TNF-α and IL-6, can indicate the degree of inflammation [8, 17, 18] . In our study, the effect of title compound on NO production in mouse RAW264.7 cells induced by LPS was examined by ELISA. PDTC was used as a reference standard. After treatment with PDTC, the express rate for NO production in RAW264.7 cells was 68.32 ± 2.69%. After treatment with title compound, the express rate of NO production was significantly decreased, reaching 48.29 ± 0.71%. The result showed that title compound displayed potential inhibitory effects on LPS-induced NO secretion compared to PDTC.
